Treatment of patients under antiplatelet medication experiencing bleeding

An anti-platelet drug and platelet technology, applied in the direction of drug combination, medical raw materials derived from algae, blood diseases, etc., can solve problems such as bleeding complications that cannot be effectively solved

Pending Publication Date: 2022-02-22
克努特·费尔克
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these products are effective in addressing bleeding complications during surgery caused by P2Y12 receptor blockade or DAPT drugs
[0009] The lack of methods or products to address complications caused by P2Y12 receptor antagonist drugs or DAPT during acute surgery often results in patients who may have to endure open chest wounds for days and receive massive blood transfusions, both of which carry additional serious Risk of infection until the bleeding stops and the surgeon can close the wound

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of patients under antiplatelet medication experiencing bleeding
  • Treatment of patients under antiplatelet medication experiencing bleeding
  • Treatment of patients under antiplatelet medication experiencing bleeding

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] The following description focuses on embodiments of the invention that are applicable to therapeutic strategies for patients receiving antiplatelet drug therapy. Especially in the treatment of patients suffering from bleeding complications during / after surgery.

[0021] During physiological primary hemostasis, platelets immediately adhere to the exposed subendothelial membrane at the site of vascular injury, become activated, and release autocrine mediators such as thromboxane A2 (TXA2) and adenosine diphosphate (ADP), This changes the conformation of the fibrinogen receptor integrin αIIbβ3 into an activated state and eventually aggregates to form a fibrinogen-bridged plug. For TXA2, thromboxane / prostaglandin receptor-α (TPα) is the major isoform of platelets and, like the receptors for thrombin (PAR-1 and PAR-4), couples to Gα12 / 13 and Gαq . For ADP, Gαq-coupled P2Y1 receptors and Gαi2-coupled P2Y12 receptors have been identified on platelets. Signaling through the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention pertains platelet endothelial aggregation receptor 1 (PEAR1) agonist for use in the treatment of bleeding in a patient wherein the patient is under antiplatelet medication. Provided is also a topical haemostat, a sealant, or an adhesive, to be used locally during surgery.

Description

[0001] field of invention [0002] The present invention relates generally to the treatment of patients under antiplatelet drug therapy with agents that modulate human platelet activation and aggregation. Especially in patients who experience bleeding complications during / after surgery. Furthermore, the present invention relates to platelet endothelial receptor 1 (PEAR1) agonists for such use, such as natural fucoidan, synthetic fucoidan-mimicking glycopolymers, such as sulfated α-L-fucoidan Glycosidic side chain sugar polymer or dextran sulfate. Background technique [0003] Human platelets, also colloquially called platelets, patrol blood vessels as sentinels of vascular integrity. Platelets play a key role in physiological hemostasis through adhesion to damaged vessel walls, agglutination, propagation of coagulation, and thrombus formation (the latter also known as "clots"). In addition, platelets then participate in fibrinolysis (the breakdown of thrombus) and repair of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K45/06A61K31/216A61K9/70A61P7/04A61K36/03A61K31/60A61K31/4365A61K31/737
CPCA61K45/00A61K45/06A61K31/216A61K9/7046A61P7/04A61K36/03A61K31/60A61K31/4365A61K31/737A61K9/7023A61K2300/00A61F2013/00463A61L15/44A61L31/16A61P7/02
Inventor 克努特·费尔克卡尔·芒努斯·伦纳特·格雷加德尼尔斯·彼得·波尔松马茨·奥洛夫·德赖法尔特
Owner 克努特·费尔克
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap